Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Author Correction: A First-in-Class Selective EGFR and PI3K Inhibitor Enables Single-Molecule Targeting of Adaptive Resistance

  • By

  • Christopher E. Whitehead

  • Elizabeth K. Ziemke

  • Christy L. Frankowski-McGregor

  • Rachel A. Mumby

  • June Chung

  • Jinju Li

  • Nathaniel Osher

  • Oluwadara Coker

  • Veerabhadran Baladandayuthapani

  • Scott Kopetz

  • Judith S. Sebolt-Leopold

  • October 12, 2026

Share

Original Source(s)

Author Correction: A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance

  • by Christopher E. Whitehead, Elizabeth K. Ziemke, Christy L. Frankowski-McGregor, Rachel A. Mumby, June Chung, Jinju Li, Nathaniel Osher, Oluwadara Coker, Veerabhadran Baladandayuthapani, Scott Kopetz, Judith S. Sebolt-Leopold

  • October 12, 2026

Related Content

Late enhancement and washout maps for distinguishing tumor progression from radiation necrosis in malignant brain tumors: an exploratory study

Short-term outcomes of a novel anti-reflux biologic flap technique versus double flap technique after laparoscopic proximal gastrectomy: a retrospective cohort study

Screening strategies for the early detection of non-cardia gastric cancer in low- to moderate-prevalence regions: Asia-Pacific gastroesophageal cancer congress consensus 2026